Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Janssen Pharmaceutica Nv patents


Recent patent applications related to Janssen Pharmaceutica Nv. Janssen Pharmaceutica Nv is listed as an Agent/Assignee. Note: Janssen Pharmaceutica Nv may have other listings under different names/spellings. We're not affiliated with Janssen Pharmaceutica Nv, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "J" | Janssen Pharmaceutica Nv-related inventors


6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors

The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one derivatives as negative allosteric modulators (nams) of the metabotropic glutamate receptor subtype 2 (“mglur2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mglur2 subtype of metabotropic receptors is involved.. ... Janssen Pharmaceutica Nv

Substituted 4-azaindoles and their use as glun2b receptor modulators

Substituted 4-azaindoles as nr2b receptor ligands. Such compounds may be used in nr2b receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by nr2b receptor activity.. ... Janssen Pharmaceutica Nv

Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid

The meglumine salt of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid (compound (1)) and pharmaceutically acceptable formulations thereof are described. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by prolyl hydroxylase activity.. ... Janssen Pharmaceutica Nv

Intranasal insert for ofc neuroprotection

. . An aesthetically pleasing intranasal nir/red light emitting device, wherein the device is a) secured in a first nostril by a spring clip securely contacting the inner surface of the opposite nostril, or b) secured in a first nostril by a retaining element (such as an adhesive) adapted to containing substantially only the inner surface of the first nostril.. . ... Janssen Pharmaceutica Nv

Small molecule inhibitors of the jak family of kinases

2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6h)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by jak, such as inflammatory bowel disease.. . ... Janssen Pharmaceutica Nv

Antimicrobial compositions comprising food approved antimicrobials and zinc pyrithione

The present invention relates to combinations of zinc pyrithione and food-approved antimicrobials which provide a synergistic antimicrobial effect. The food approved antimicrobials are selected from sodium sulfite, sodium bisulfite, potassium metabisulfite, potassium sulfite, calcium sulfite, calcium hydrogen sulfite, potassium hydrogen sulfite, sodium nitrate, potassium nitrate, and lysozyme. ... Janssen Pharmaceutica Nv

Anhydrous crystalline form of (1s)-1,5-anhydro-1-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-d-glucitol

. . The present invention is directed to an anhydrous crystalline for of (1s)-1,5-anhydro-1-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-d-glucitol, pharmaceutical compositions containing said anhydrous crystalline form and its use in the treatment glucose-related disorders such as type 2 diabetes mellitus and syndrome x.. . ... Janssen Pharmaceutica Nv

Antibodies to aripiprazole haptens and use thereof

Disclosed is an antibody which binds to aripiprazole, which can be used to detect aripiprazole in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of aripiprazole, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.. ... Janssen Pharmaceutica Nv

Dosing regimen associated with long acting injectable paliperidone esters

The present invention provides a method of treating patients in need of treatment with long acting injectable paliperidone palmitate formulations.. . ... Janssen Pharmaceutica Nv

Antibodies to pyroglutamate amyloid-b and uses thereof

The invention provides an antibody or antigen binding fragments thereof that binds to 3pe aβ and methods of making and using the antibody or antigen binding fragment thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of alzheimer's disease or other β-amyloid-related diseases.. ... Janssen Pharmaceutica Nv

Methods of identifying schizophrenia patients at risk for relaspe

The invention provides methods of identifying schizophrenia patients at risk for relapse. The invention also provides methods of early detection of schizophrenic relapse. ... Janssen Pharmaceutica Nv

Crystalline forms of 4-cyano-n-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyltetrahydro-2h-pyran-4-yl)pyridin-3-yl)-1h-imidazole-2-carboxamide

The present disclosure discusses crystalline forms of 4-cyano-n-[2-(4,4-dimethylcyclohex-1-yl)-6-(2,2,6,6-tetramethyltetrahydro-2h-pyran-4-yl)pyridine-3-yl]-1h-imidazole-2-carboxamide.. . ... Janssen Pharmaceutica Nv

Immunoglobulins and uses thereof

. . The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.. ... Janssen Pharmaceutica Nv

Substituted 1h-imidazo[4,5-b]pyridin-2(3h)-ones and their use as glun2b receptor modulators

Substituted 1h-imidazo[4,5-b]pyridin-2(3h)-ones as nr2b receptor ligands. Such compounds may be used in nr2b receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by nr2b receptor activity.. ... Janssen Pharmaceutica Nv

05/03/18 / #20180117170

Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors

. . The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic pyy peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. ... Janssen Pharmaceutica Nv

05/03/18 / #20180117169

Haptens of aripiprazole

The invention relates to compounds of formula i, wherein r1, r2, and r3 are defined in the specification, useful for the synthesis of novel conjugates and immunogens derived from aripiprazole. The invention also relates to conjugates of an aripiprazole hapten and a protein.. ... Janssen Pharmaceutica Nv

05/03/18 / #20180116964

Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile

The present invention relates to the fumarate salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile, pharmaceutical compositions comprising as active ingredient said salt and to processes for their preparation.. . ... Janssen Pharmaceutica Nv

04/19/18 / #20180105606

Antibodies to quetiapine haptens and use thereof

Disclosed is an antibody which binds to quetiapine, which can be used to detect quetiapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of quetiapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.. ... Janssen Pharmaceutica Nv

04/05/18 / #20180092930

Methods of diagnosing and treating abiraterone acetate- glucocorticoid -resistant or -sensitive metastatic castration resistant prostate cancer

Disclosed herein are novel biomarkers for detecting resistance and sensitivity to abiraterone acetate-glucocorticoid treatment in a patient having metastatic castration resistant prostate cancer. Also provided are methods of diagnosing and treating abiraterone acetate-glucocorticoid resistant and abiraterone acetate-glucocorticoid sensitive metastatic castration resistant prostate cancer.. ... Janssen Pharmaceutica Nv

03/15/18 / #20180071295

Bruton's tyrosine kinase inhibitor combinations and uses thereof

. . Disclosed herein are methods, compositions, and kits for treating a b-cell malignancy comprising administering a combination of a btk inhibitor (e.g. Ibrutinib) and a pim inhibitor. ... Janssen Pharmaceutica Nv

03/08/18 / #20180065955

Indazole derivatives useful as glucagon receptor antagonists

. . The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as type ii diabetes mellitus and obesity.. . ... Janssen Pharmaceutica Nv

03/08/18 / #20180065934

Indazole derivatives useful as glucagon receptor antagonists

The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as type ii diabetes mellitus and obesity.. . ... Janssen Pharmaceutica Nv

03/08/18 / #20180064686

Indole derivatives useful as glucagon receptor antagonists

The present invention is directed to indole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as type ii diabetes mellitus and obesity.. . ... Janssen Pharmaceutica Nv

02/22/18 / #20180050107

Neurosteroid compositions and methods of use thereof

. . . . Provided herein are compositions comprising neurosteroids and saponins, methods of making said compositions, and methods of utilizing said compositions to treat or prevent perinatal depression (pnd) in a subject in need thereof.. . ... Janssen Pharmaceutica Nv

02/08/18 / #20180037651

Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof

Provided herein are antibodies that specifically bind to gprc5d. Also described are related polynucleotides capable of encoding the provided gprc5d-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. ... Janssen Pharmaceutica Nv

02/01/18 / #20180028521

Methods of treating prostate cancer

. . Disclosed are methods of treating prostate cancer by administering niraparib to a human in need thereof.. . ... Janssen Pharmaceutica Nv

01/25/18 / #20180022827

Antibodies to risperidone haptens and use thereof

. . Disclosed is an antibody which binds to risperidone, which can be used to detect risperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of risperidone, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.. ... Janssen Pharmaceutica Nv

01/25/18 / #20180022704

Process for the preparation of histamine h3 receptor modulators

The present invention is directed to novel processes for the preparation of histamine h3 receptor modulators, in the treatment of for example, cognitive disorders, sleep disorders and/or psychiatric disorders.. . ... Janssen Pharmaceutica Nv

01/18/18 / #20180016264

Salt forms of 4-cyano-n-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyltetrahydro-2h-pyran-4-yl)pyridin-3-yl)-1h-imidazole-2-carboxamide

The present disclosure discusses salt forms of 4-cyano-n-[2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyltetrahydro-2h-pyran-4-yl)pyridin-3-yl]-1h-imidazole-2-carboxamide.. . ... Janssen Pharmaceutica Nv

01/11/18 / #20180009814

Synthesis of a bruton?s tyrosine kinase inhibitor

. . Described herein is the synthesis of bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo [3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one.. . ... Janssen Pharmaceutica Nv

01/11/18 / #20180009783

Substituted 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides and methods of making the same

The present invention relates to certain intermediates useful in the preparation of certain benzoimidazol-2-yl pyrimidines and processes for preparing them. In particular, the present invention relates to various 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides as useful intermediates in the preparation of compounds including. ... Janssen Pharmaceutica Nv

01/04/18 / #20180000810

Dispersible compositions

. . The present invention is concerned with dispersible compositions comprising bedaquiline fumarate as an active ingredient. Such compositions are useful in the treatment of tuberculosis and their inherent dispersibility properties lend themselves to be useful in particular amongst the pediatric or geriatric population.. ... Janssen Pharmaceutica Nv

12/28/17 / #20170368025

Combination of canagliflozin and probenecid for the treament of hyperuricemia

The present invention is directed to methods for treating hyperuricemia and related disorders, comprising co-therapy with canagliflozin and probenecid.. . ... Janssen Pharmaceutica Nv

12/21/17 / #20170362222

1,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of mglur2 receptors

. . . . The present invention relates to novel 1,2,4-triazolo[4,3-a]pyridine compounds as positive allosteric modulators (pams) of the metabotropic glutamate receptor subtype 2 (“mglur2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which mglur2 subtype of metabotropic receptors is involved.. ... Janssen Pharmaceutica Nv

11/30/17 / #20170343569

Antibodies to olanzapine haptens and use thereof

. . Disclosed is an antibody which binds to olanzapine, which can be used to detect olanzapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of olanzapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.. ... Janssen Pharmaceutica Nv

11/23/17 / #20170334906

New compounds as nik inhibitors

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of nf-κb-inducing kinase (nik—also known as map3k14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.. ... Janssen Pharmaceutica Nv

11/23/17 / #20170334900

New pyrazole derivatives as nik inhibitors

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of nf-κb-inducing kinase (nik—also known as map3k14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.. ... Janssen Pharmaceutica Nv

11/16/17 / #20170327514

Flap modulators

The present invention relates to compounds of formula (i), or a form thereof wherein ring a, r1, l and r2 are as defined herein, useful as flap modulators. The invention also relates to pharmaceutical compositions comprising compounds of formula (i). ... Janssen Pharmaceutica Nv

11/16/17 / #20170327492

Trifluoromethyl alcohols as modulators of roryt

The present invention comprises methods of making 5-(2,3-dichloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-n-(2-hydroxy-2-methylpropyl)-4-(r1-1-carbonyl)thiazole-2-carboxamide, wherein r1 is defined in the specification.. . ... Janssen Pharmaceutica Nv

11/09/17 / #20170320950

Anti-vista antibodies and fragments, uses thereof, and methods of identifying same

. . . . . . The present invention relates to antibodies and fragments that bind to a v-domain ig suppressor of t cell activation (vista), and methods of eliciting certain biological responses using the antibodies. Compositions and methods of using anti-vista antibodies in combination with one or more antibodies that bind to immune checkpoint proteins are also provided.. ... Janssen Pharmaceutica Nv

10/26/17 / #20170304254

4-(phenoxyalkyl)thio)-phenoxyacetic acids and analogs

The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as ppar delta modulators to treat or inhibit the progression of, for example, dyslipidemia.. . ... Janssen Pharmaceutica Nv

10/05/17 / #20170283431

Inhibitors of bruton's tyrosine kinase and method of their use

. . . . . . The present disclosure is directed to compounds of formula i′ and methods of their use and preparation, as well as compositions comprising compounds of formula i′.. . ... Janssen Pharmaceutica Nv

10/05/17 / #20170283430

Inhibitors of bruton's tyrosine kinase and method of their use

The present disclosure is directed to compounds of formula (i) and methods of their use and preparation, as well as compositions comprising compounds of formula (i).. . ... Janssen Pharmaceutica Nv

09/28/17 / #20170273976

6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors

The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one derivatives as negative allosteric modulators (nams) of the metabotropic glutamate receptor subtype 2 (“mglur2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mglur2 subtype of metabotropic receptors is involved.. ... Janssen Pharmaceutica Nv

09/21/17 / #20170267684

A deuterated triazolopyridazine as a kinase modulator

The invention is directed to a triazolopyridazine compound of formula (i), n-oxides, pharmaceutically acceptable salts and solvates thereof, wherein d represents deuterium, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-met, and the use of such compounds to reduce or inhibit kinase activity of c-met in a cell or a subject, and modulate c-met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.. ... Janssen Pharmaceutica Nv

09/21/17 / #20170267682

6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors

The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one derivatives as negative allosteric modulators (nams) of the metabotropic glutamate receptor subtype 2 (“mglur2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mglur2 subtype of metabotropic receptors is involved.. ... Janssen Pharmaceutica Nv

09/14/17 / #20170258790

Methods of treating depression using orexin-2 receptor antagonists

. . The present disclosure is directed to, inter alia, methods of treating a subject suffering from or diagnosed with depression, comprising administering to a subject in need of such treatment an effective amount of a compound of formula (i), or a pharmaceutically acceptable salt thereof, wherein r1 to r4 are described herein and wherein the compound is administered prior to sleep.. . ... Janssen Pharmaceutica Nv

09/07/17 / #20170252344

Compositions containing ibrutinib

Discussed herein are pharmaceutical compositions containing ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, b-cell proliferative disorders such as non-hodgkin lymphoma (diffuse large b cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. ... Janssen Pharmaceutica Nv

08/24/17 / #20170240653

Antibodies to olanzapine haptens and use thereof

Disclosed is an antibody which binds to olanzapine, which can be used to detect olanzapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of olanzapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.. ... Janssen Pharmaceutica Nv

08/17/17 / #20170233479

Anti-vista antibodies and fragments, uses thereof, and methods of identifying same

. . The present invention relates to antibodies and fragments that bind to a v-domain ig suppressor of t cell activation (vista), and methods of eliciting certain biological responses using the antibodies. Methods of identifying anti-vista antibodies capable of eliciting certain biological responses are also included.. ... Janssen Pharmaceutica Nv

08/10/17 / #20170226089

Substituted 1,2,3-triazoles as nr2b-selective nmda modulators

Substituted 1,2,3-triazoles as nr2b receptor ligands. Such compounds may be used in nr2b receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by nr2b receptor activity.. ... Janssen Pharmaceutica Nv

08/03/17 / #20170218466

Detection of circulating jc polyomavirus (jcpyv) micrornas as biomarker for jcpyv infection

The invention concerns the quantitative analysis of circulating jcpyv micrornas (mirna) in body fluid and its use as biomarker for jcpyv infection.. . ... Janssen Pharmaceutica Nv

08/03/17 / #20170217972

6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors

The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one derivatives as negative allosteric modulators (nams) of the metabotropic glutamate receptor subtype 2 (“mglur2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mglur2 subtype of metabotropic receptors is involved.. ... Janssen Pharmaceutica Nv

08/03/17 / #20170217971

6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors

The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one derivatives as negative allosteric modulators (nams) of the metabotropic glutamate receptor subtype 2 (“mglur2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mglur2 subtype of metabotropic receptors is involved.. ... Janssen Pharmaceutica Nv

08/03/17 / #20170215766

Sensor device and carriers

Disclosed herein are systems comprising sensor devices that may be affixed to a patient and used to perform clinical measurements such as measurements for calculating a basmi score. A first sensor device is configured to be successively attached to each of a wrist carrier, an ankle carrier, and a headset carrier. ... Janssen Pharmaceutica Nv

07/20/17 / #20170204198

Antibodies to aripiprazole haptens and use thereof

. . Disclosed is an antibody which binds to aripiprazole, which can be used to detect aripiprazole in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of aripiprazole, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.. ... Janssen Pharmaceutica Nv

07/13/17 / #20170198357

R2r1/2 in diagnosis and therapy

The present invention stems from the finding that two genes designated r2r1 and r2r2, play important roles in tissue development and cancer biology. In particular, the inventors have discovered that these two genes are expressed in pulmonary cells and are required for late branching morphogenesis of pulmonary epithelium and endothelium and support the development/maintenance of the refined three dimensional architecture of the lung. ... Janssen Pharmaceutica Nv

07/06/17 / #20170192016

N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses

This invention relates to antibodies, including specified portions or variants, specific for at least the human amyloid-beta_11 n-terminal site, i.e. Aβ11-x peptides. ... Janssen Pharmaceutica Nv

06/22/17 / #20170176474

Antibodies to quetiapine and use thereof

. . . . . . . . Disclosed is an antibody or a binding fragment thereof which binds to quetiapine, which can be used to detect quetiapine in a sample such as in a competitive immunoassay method. The antibody or the fragment thereof can be used in a lateral flow assay device for point-of-care detection of quetiapine, including multiplex detection of aripiprazole, quetiapine, olanzapine, and risperidone in a single lateral flow assay device.. ... Janssen Pharmaceutica Nv

06/22/17 / #20170176473

Antibodies to risperidone and use thereof

Disclosed is an antibody or a binding fragment thereof that binds to risperidone, which can be used to detect risperidone in a sample such as in a competitive immunoassay method. The antibody or fragment thereof can be used in a lateral flow assay device for point-of-care detection of risperidone, including multiplex detection of aripiprazole, quetiapine, olanzapine, and risperidone in a single lateral flow assay device.. ... Janssen Pharmaceutica Nv

06/15/17 / #20170164630

Milk filtration devices and methods for filtering

A method of cleaning mother's milk, involving ex vivo contacting mother's milk having an initial concentration of an antidepressant therein with a solid substrate (preferably a porous substrate) adapted to remove the antidepressant from the milk to produce a cleansed milk product having a reduced concentration of the antidepressant.. . ... Janssen Pharmaceutica Nv

06/08/17 / #20170158678

Substituted pyridine derivatives useful as c-fms kinase inhibitors

. . The present invention is directed to substituted pyridine derivatives, pharmaceutical compositions containing said derivatives and the use of said derivatives in the treatment of disorders mediated by c-fms kinase. The present invention is further directed to a process for the preparation of said substituted pyridine derivatives.. ... Janssen Pharmaceutica Nv

05/11/17 / #20170129968

Antibodies to paliperidone haptens and use thereof

Disclosed is an antibody which binds to paliperidone, which can be used to detect paliperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of paliperidone, including multiplex detection of aripiprazole, olanzapine, quetiapine, risperidone and paliperidone in a single lateral flow assay device.. ... Janssen Pharmaceutica Nv

05/11/17 / #20170129901

Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators

Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.. ... Janssen Pharmaceutica Nv

05/11/17 / #20170128451

Dosing regimen associated with long acting injectable paliperidone esters

The present invention provides a method of treating patients in need of treatment with long acting injectable paliperidone palmitate formulations.. . ... Janssen Pharmaceutica Nv

05/04/17 / #20170121420

Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof

. . Provided herein are antibodies that specifically bind to il1rap. Also described are related polynucleotides capable of encoding the provided il1rap-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. ... Janssen Pharmaceutica Nv

05/04/17 / #20170121309

Substituted 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides and methods of making the same

The present invention relates to certain intermediates useful in the preparation of certain benzoimidazol-2-yl pyrimidines and processes for preparing them. In particular, the present invention relates to various 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides as useful intermediates in the preparation of compounds including. ... Janssen Pharmaceutica Nv

04/06/17 / #20170095403

Vial holder devices and systems

. . . . A packaging system is provided for securely and irreversibly holding a sterile product. The packaging system includes a primary packaging holder and a secondary packaging holder. ... Janssen Pharmaceutica Nv

03/30/17 / #20170088531

Benzo-fused heterocyclic derivatives useful as agonists of gpr120

The present invention is directed to benzo-fused heterocyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by gpr120. More particularly, the compounds of the present invention are agonists of gpr120, useful in the treatment of, such as for example, type ii diabetes mellitus.. ... Janssen Pharmaceutica Nv

03/16/17 / #20170072061

Haptens of aripiprazole

. . The invention relates to compounds of formula i, wherein r1, r2, and r3 are defined in the specification, useful for the synthesis of novel conjugates and immunogens derived from aripiprazole. The invention also relates to conjugates of an aripiprazole hapten and a protein.. ... Janssen Pharmaceutica Nv

03/16/17 / #20170071970

Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders

The present invention is directed to the use of co-therapy comprising administration of canagliflozin and phentermine for the treatment of obesity and obesity related disorders. More particularly, the present invention is directed to co-therapy for treating obesity, for promoting weight loss and/or for suppressing appetite; for treating, delaying, slowing the progression of and/or preventing metabolic disorders (including for example type 2 diabetes mellitus); for treating, delaying, slowing the progression of and/or preventing renal or fatty liver disorders (including for example nash, nafld, etc.); for treating, delaying, slowing the progression of and/or preventing sleep disorders (including for example sleep apnea); for providing cardiovascular protection; for treating, delaying, slowing the progression of and/or preventing cardiovascular events (including major adverse cardiac events (mace) such as myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal or non-fatal cerebrovascular accident, peripheral arteriopathy, aortic events, hospitalization due to congestive heart failure, etc.); and/or for extending or prolonging life span.. ... Janssen Pharmaceutica Nv

03/02/17 / #20170059568

Identification of jc viral epitopes by cytotoxic t lymphocytes in healthy individuals and their use in assays

. . . . . . The invention relates to a method to predict the onset and/or development of pml in a patient or in an immunosuppressed patient by detection of jcv specific ctl's in blood of said patient using any of the ten (10) jcv amino acid sequences seq id no 1-10 separately or in combination with each other.. . ... Janssen Pharmaceutica Nv

03/02/17 / #20170057929

Benzimidazole derivatives useful as cb-1 inverse agonists

The present invention is directed to benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the cb-1 receptor; more particularly, use in the treatment of disorders and conditions responsive to inverse agonism of the cb-1 receptor. More particularly, the compounds of the present invention are useful in the treatment of metabolic disorders.. ... Janssen Pharmaceutica Nv

03/02/17 / #20170057925

Indazole derivatives useful as cb-1 inverse agonists

The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the cb-1 receptor; more particularly, use in the treatment of disorders and conditions responsive to inverse agonism of the cb-1 receptor. More particularly, the compounds of the present invention are useful in the treatment of metabolic disorders.. ... Janssen Pharmaceutica Nv

03/02/17 / #20170057919

Process for the preparation of histamine h3 receptor modulators

The present invention is directed to novel processes for the preparation of histamine h3 receptor modulators, in the treatment of for example, cognitive disorders, sleep disorders and/or psychiatric disorders.. . ... Janssen Pharmaceutica Nv

02/23/17 / #20170051068

Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof

Provided herein are antibodies that immunospecifically bind to bcma. Also described are related polynucleotides capable of encoding the provided bcma-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. ... Janssen Pharmaceutica Nv

02/23/17 / #20170051061

Anti-vista antibodies and fragments

The present invention relates to novel antibodies and fragments that bind to a v-domain ig suppressor of t cell activation (vista), and methods of making and using same. Methods of use include methods of treatment of cancer, including leukemias, lymphomas, solid tumors and melanomas.. ... Janssen Pharmaceutica Nv

02/16/17 / #20170045537

Antibodies to paliperidone and use thereof

. . . . . . Disclosed is an antibody which binds to paliperidone, which can be used to detect paliperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of paliperidone, including multiplex detection of aripiprazole, quetiapine, olanzapine, and risperidone/paliperidone in a single lateral flow assay device.. ... Janssen Pharmaceutica Nv

02/09/17 / #20170037152

Antibodies to olanzapine and use thereof

Disclosed is an antibody which binds to olanzapine, which can be used to detect olanzapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of olanzapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.. ... Janssen Pharmaceutica Nv

02/02/17 / #20170030936

Antibodies to aripiprazole and use thereof

. . . . Disclosed is an antibody which binds to aripiprazole, which can be used to detect aripiprazole in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of aripiprazole, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.. ... Janssen Pharmaceutica Nv

01/12/17 / #20170008890

Substituted 4-azaindoles and their use as glun2b receptor modulators

. . . . Substituted 4-azaindoles as nr2b receptor ligands. Such compounds may be used in nr2b receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by nr2b receptor activity.. ... Janssen Pharmaceutica Nv








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Janssen Pharmaceutica Nv in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Janssen Pharmaceutica Nv with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###